Hyperlipidemias Flashcards

1
Q

HMG-CoA reductase inhibitors
adverse effects
-relatively free of adverse effects
-may elevate serum levels of _____ enzymes and cause ______

less frequent adverse effects are:
______, ______, _______: destruction of muscle cells releasing myoglobin leading to ____ failure
-increase in ALT/AST (liver homeostasis)
-hepatic toxicity with concurrent ____ use

A
hepatic
hepatitis
myalgia, myopathy, rhabdomyolysis
renal
alcohol
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

bile acids-binding resin
Cholestyramine & Colestipol
-Cationic ____ molecular weight polymers containing ___
-chloride ion is exchanged for ____ acids in the gut: forming ___________
-resin bile complex cannot be reabsorbed in the distal ______
-to obtain max effect, they must be taken before each ____ and at ____
-the bile acid resin complex is excreted via the _____

-bind to digoxin, levothyroxine, warfarin

moderately effective
reduce LDL by 28%
excellent safety record bc it is not _______ and there is no ______
these drugs cause an decreased absorption of ___ soluble vitamins
-these drugs should NOT be used in pts with ___

A
large
chloride
bile
bile acid-resin complex
ileum
meal, bedtime
feces
absorbed
hepatic first effect
fat
IBD
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

fibric acids

  • activated _____ results in change in lipid metabolism
  • increased ____ activation of lipoprotein lipase
  • increased uptake of _____ rich lipoproteins
  • reduce serum ____ and ____ levels
  • -reduction in triglyceride levels is accompanoied by an increase in ____ and ______
adverse effects
GI: constipation, fecal impaction
-allergic reactions
blood cell deficiences
-\_\_\_\_\_\_\_ and \_\_\_\_\_\_ (do not administer with \_\_\_\_)
A
PPAR-alpha
muscle
triglyceride
VLDL
triglyceride
HDL, cholesterol
rhabdomyolysis
myalgia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

dyslipidemias cause:

  • _______
  • _______
  • ____
  • ____
  • peripheral __________ disease
  • elevated ___/low ____
  • elevated ______
A
atherosclerosis
hypertension
MI
stroke
arterial occlusive
LDL, HDL
triglycerides
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Proprotein Convertase Subtilisin/Kexin type 9 Inhibition

  • PCSK9 is an enzyme that degrades the _______ on hepatocytes
  • it decreases the number of LDL receptors on surface of liver cells
  • increases plasma conc of ____
  • overexpression increases susceptibility to atherosclerotic lesion development
  • _____ results in major reduction in the plasma conc of LDL-C
A

LDL receptor
LDL-C
inhibition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

cholesterol balance

-cholesterol is converted in liver to ____ and secreted in the _____
-____ elimination occurs but most cholesterol is recycled by high affinity transport proteins in the distal ileum back to the liver and back into bile
this is called ____________

A

bile acids
bile
fecal
enterohepatic circulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

HDL formation

HDL formation occurs in the _____ and _______

  • _____ HDL particles are disc shaped and are bound to _______
  • this binding converts cholesterol into _________
  • these esters migrate to the core of the molecule called ________ particles which is spherical in shape
  • HDL serves as a reservoir for exchangeable ________ and plays a role in cholesterol _______
  • HDL removes excessive _____ from cells and transports it to the ____
  • cholesterol efflux occurs when _______ cholesterol molecules from plasma membrane of cells bind to HDL particles
  • this extrahepatic cholesterol is carried by HDL to the liver and this _______ explains HDL’s protective role
A
liver
small intestine
pre beta
PLTP (phospholipid transfer protein)
cholesterol esters
alpha HDL
apolipoproteins
homeostasis
cholesterol
liver
unesterified
reverse transport
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q
drugs for hypercholesteremia
1
2
3
4
A

HMG coA reductase inhibitors (statins)
bile acid binding resins
fibric acid derivatives
misc drugs & natural compouds

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

therapies that target high-density lipoprotein

  • the concentration of _____ is a robust inverse predictor of the risk of having an ASCVD event
  • infusion of a preparation of reconstituted HDL reduces coronary _____
  • HDLs also have several potentially cardioprotective proprteies including promotion of efflux of _____ from macrophages and inhibition of vascular ______. HDLs also have ____ and ____ effects
A
HDL-C
atheroma
cholesterol
inflammation
antioxidant
antithrombotic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

HMG-CoA reductase inhibitors

  • reduced levels of liver cholesterol compensate by synthesizing (up-regulating) ____ receptors to draw cholesterol out of circulation
  • _____ cleave membrane-bound sterol regulatory element binding proteins (SREBP), which then migrate to the _____ and bind to the sterol response elements (SRE) which increase transcription of various proteins, most notably _______
  • the ldl receptor is transported to the ____ cell membrane and binds to passing LDL and VLDL particles, mediating their uptake into the liver (____)
  • this results in ____ LDL circulating in blood
A
LDL receptors
proteases
nucleus
LDL receptors
liver
bile
less
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

fibric acid derivatives

  • indicated for familial _______ and marked ___ deficiency
  • fibrates bind to and activate ___ alpha receptor in hepatocytes, skeltal muscle, macrophages and heart tissue

-derivatives of fibric acid or fibrate
_____: first drug in this class, not used clinically due to numerous side effects
-_____
-______

A
hypertriglyceridemia
HDL
PPAR
clofribate
fenofibrate
gemfibrozil
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

LDL particles

  • LDL particles not taken up by LDL receptors in tissues migrate into the _____ of blood vessels and bind to _______
  • they are subject to ______ resulting in lipid _________
  • this modified LDL is internalized by _______ receptors in phagocytic monocytes
  • continued accumulation of oxidized LDL results in the formation of _______ which are _____ rich phagocytes
  • foam cells may undergo _____ and release ______
  • this promotes local inflammatory response
  • _______ is initiated
  • there is release of matrix _________ which may destabilize atherosclerotic plaques
A
intima
peptidoglycans
oxidation
perioxidation
scavenger
foam cells
cholesterol
apoptosis
free radicals
atherosclerosis
metalloproteinases
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

niacin

  • _______
  • ___ soluble B3
  • substrate in the synthesis of ___ and ___
  • decrease ___ and ___ levels
  • decrease production of hepatic ___ due to fall in production of triglycerides
  • VLDL are precursors of ___, thus a fall in VLDL leads to a decerase in LDL production
  • increases the conc of ___
  • decreased breakdown of ____ lipids causes a decrease in ____ cholesterol availability
  • pharmacological action needs ___ doses
A
nicotinic acid 
water
NAD, NADP
VLDL, LDL
VLDL
LDL
HDL
complex
free
high
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Lipids

  • Lipids serve as energy sources, ______ precursors and signal molecules and are packed within _______
  • lipoproteins are macromolecular aggregates that transport ______ and ______ in the blood
  • ______: large, not dense, high lipid content
  • ____: smaller, less dense, moderate-high lipid content
  • ____: very small, very dense, low lipid content
  • _________ which deliver fatty acids to muscle for ___ synthesis and for storage in _____ tissue/______
  • -________
  • –component of cell membrane/precursor to ______ and steroid compounds

–______: main storage form of fuel

-elevation of both cholesterol & triglycerides play an important role in ________ and other disorders

A
hormone
lipoporteins
triglycerides & cholesterol
chylomicrons
LDL
HDL
apolipoproteins
ATP
adipose
hepatocytes
cholesterol
steroid
triglycerides
heart diseases
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

HMG-CoA reductase inhibitors

  • statins act by _______ inhibiting HMG-CoA reductase (rate limiting enzyme of the ______ pathway)
  • because statins are similar in structure to HMG-CoA on a molecular level, they will fit into the enzymes active site and compete
  • this reduces the rate HMG-CoA is able to produce ________, the next molecule in cascade that eventually produces cholesterol

by inhiting HMG-CoA reductase, statins block pathway for synthesizing _____ in the liver

  • most circulating cholesterol comes from ______ manufacture rather than diet
  • lowered ___ production results in lower blood _____ levels
  • cholesterol synthesis appears to occur mostly at _____
  • ___ half life statins work at night best
A
competitively
mevalonate
.mevalonate
cholesterol
internal
liver
cholesterol
night
short
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

HMG-CoA reductase inhibitors
Drug causing -myopathies/rhabdomyolysis: _____ & _____
-inhibit metabolism of HMG-CoA inhibitors: _____________
-Warfarin: increase in warfarin blood levels
-_______: may increase serum conc of HMG-CoA
-______: INCREASE serum conc of simvastatin
-______: DECREASE serum conc of simvastatin
_______: increase the serum conc of HMG-CoA reductase inhibitors

A
fibric acid/niacin
macrolide antibiotics
cochicine
diltiazem
efavirenz
grapefruit juice
17
Q

inhibitors of cholesterol absorption

  • reduce cholesterol absorption by small intestine
  • includes both ____ and ____ cholesterol
  • also inhibit production of hepatic. ____
  • available: plant sterols (_____: present in fruits and veggies)

_______: decreases cholesterol transport from the _____ into ______ reducing absorption by 50%
-does not reduce absorption of _____ and ____ or ___ soluble vitamins
-decreased plasma LDL, decreased chylomicron cholesterol, decreased liver LDL decreased VLDL production
very effective in combo w ______

A
dietary, biliary
VLDL
stanons
ezetimibe
micelles
enterocytes
fatty acids, triglycerides, fat
statin
18
Q

OMEGA 3 FATTY ACIDS
____ & ____
-‘___ oils’
-reduce plasma _____ by up to 50%
-regulate nuclear transcription factors such as _____
-decrease triglyceride biosythesis and increased fatty oxidation by the liver
Lovaza: OTC 4 gms/day

A

EPA, DHA
fish
triglycerides
PPAR

19
Q

pharmacological consequences of HMG-CoA

  • decreased ______: decreased C-reactive protein
  • reversal of endothelial dysfunction: improved _____ response to NO
  • decreased ______/_____ formation
  • improved _____ of atherothrombotic plaque
  • decrease in cardiovascular morbidity and mortality
  • _____ is least potent
  • ________/_____ most potent
A
inflammation
vasodilator
thrombosis/atheroma
stability
fluvastatin
atorvastatin/rosuvastatin
20
Q

niacin adverse effects
-skin: mild to severe cutaneous ____; _____; hyperpigmentation; ___ skin
-_____ effects mediated by prostaglandins
-cardiovascular: atrial fib; hypotension
GI: dyspepsia, vomiting, diarrhea, jaundice
-hyperuricemia
-impaired ____ sensitivity
-potentiation of ___ induced myopathy with HMG coa reductase inhibitors

A
flushing
pruritus
dry
vasodilating
insulin
statin
21
Q

CAUSES of hyperlipidemia

  • _____
  • _____
  • chronic ____ failure
  • _____thyroidism
  • _______ storage disease
  • ______
  • physiological ____
  • ______ excess
  • ________
  • ____ hormone replacement therapy
  • ________, ______, ______, ______ inhibitors
A
diet
diabetes
renal
hypo
glycogen
sepsis
stress
alcohol
lipodystrophy
oral
beta blockers, dieuretics, glucocorticoids, protease
22
Q

HMG-CoA reductase Inhibitors
Statins
-enable more ___ to be delivered to the liver resulting in a 60% _____ in serum LDL cholesterol (70% liver uptake/30% other tissues)
-low _______/ good safety profile
-large _________ metabolism
-lovastatin and. simvastatin are ______
-other statins are active compounds
-metabolized via CYP450 therefore drug interaction with other drugs metabolized by same enzyme
-very effective in treatment of __________

A
LDL
reduction
bioavailability
extensive first pass
prodrugs
hyperlipidemia